StonvexLoading…
StonvexStonvexStonvexCore line items from ABUS's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.
| Metric | Annual 2025 2025-12-31 | Annual 2024 2024-12-31 | Annual 2023 2023-12-31 | Annual 2022 2022-12-31 |
|---|---|---|---|---|
Revenue | $14.08M | $6.17M | $18.14M | $39.02M |
Operating Income | $-38.16M | $-76.32M | $-78.10M | $-65.46M |
Net Income | $-33.50M | $-69.92M | $-72.85M | $-69.46M |
EPS (Diluted) | $-0.17 | $-0.38 | $-0.44 | $-0.46 |
Total Assets | $94.62M | $131.71M | $144.40M | $195.42M |
Total Liabilities | $18.04M | $34.34M | $38.38M | $58.57M |
Cash & Equivalents | $18.01M | $36.33M | $26.29M | $30.78M |
Free Cash Flow OCF − CapEx | $-39.64M | $-65.03M | $-86.94M | $-35.87M |
Shares Outstanding | 192.53M | 189.96M | 169.87M | 157.46M |